Hengrui Pharma's stock surged 10.65% in the pre-market trading session on Monday, following the announcement of a significant licensing agreement with global pharmaceutical giant GSK. The deal grants GSK exclusive rights to Hengrui's HRS-9821 project and options for up to 11 additional projects, excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan.
According to the terms of the agreement, GSK will make an initial payment of $500 million to Hengrui Pharma. The Chinese pharmaceutical company stands to potentially receive a total of approximately $12 billion if all projects are granted exclusive options and all development, registration, and sales milestones are achieved successfully.
This substantial deal represents a major breakthrough for Hengrui Pharma, significantly boosting its global presence and financial prospects. The market's enthusiastic response, as evidenced by the sharp rise in stock price, reflects investors' optimism about the company's future growth potential and the validation of its drug development capabilities by a leading international pharmaceutical company.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。